Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results

Steffen Böhm; Nhu Le; Michelle Lockley; Elly Brockbank; Asma Faruqi; Ian Said; Arjun Jeyarajah; Rekha Wuntakal; Blake Gilks; Naveena Singh

doi:10.1136/ijgc-2018-000092

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

other Versions

You are currently viewing an earlier version of this article (January 25, 2019).
View the most recent version of this article

Original Article

Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Read the full text or download the PDF:

Log in using your username and password